| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2000PNAS...97.5633W |
| P356 | DOI | 10.1073/PNAS.97.10.5633 |
| P932 | PMC publication ID | 25880 |
| P698 | PubMed publication ID | 10805816 |
| P5875 | ResearchGate publication ID | 235610809 |
| P50 | author | Tomas Hökfelt | Q2440397 |
| Jesper Wengel | Q39943435 | ||
| P2093 | author name string | C Wahlestedt | |
| M Ossipov | |||
| J Lai | |||
| K Ren | |||
| L Good | |||
| F Porreca | |||
| T Johnsson | |||
| J Skouv | |||
| C Broberger | |||
| P Salmi | |||
| A Koshkin | |||
| J Kela | |||
| H Oerum | |||
| M H Jacobsen | |||
| N Jakobsen | |||
| P2860 | cites work | Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate | Q24564458 |
| Structural studies of LNA:RNA duplexes by NMR: conformations and implications for RNase H activity | Q27627031 | ||
| Applications of peptide nucleic acids | Q33536459 | ||
| Brain as a unique antisense environment | Q33587542 | ||
| Fomivirsen | Q33588545 | ||
| Peptide nucleic acids (PNA) and PNA-DNA chimeras: from high binding affinity towards biological function. | Q36899175 | ||
| Selective loss of delta opioid analgesia and binding by antisense oligodeoxynucleotides to a delta opioid receptor | Q38309388 | ||
| Modification of phosphorothioate oligonucleotides yields potent analogs with minimal toxicity for antisense experiments in the CNS. | Q38331826 | ||
| Characterization of antinociception to opioid receptor selective agonists after antisense oligodeoxynucleotide-mediated "knock-down" of opioid receptor in vivo. | Q38359901 | ||
| Studies on the direct spinal action of narcotics in the production of analgesia in the rat | Q39156279 | ||
| Antisense oligonucleotide strategies in neuropharmacology | Q40744215 | ||
| A good antisense molecule is hard to find | Q41736928 | ||
| Nucleosides with a twist. Can fixed forms of sugar ring pucker influence biological activity in nucleosides and oligonucleotides? | Q42554048 | ||
| Antisense oligodeoxynucleotide to a delta-opioid receptor selectively blocks the spinal antinociception induced by delta-, but not mu- or kappa-opioid receptor agonists in the mouse | Q44336744 | ||
| Characterization of supraspinal antinociceptive actions of opioid delta agonists in the rat. | Q44341836 | ||
| An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice | Q44343549 | ||
| A biosynthetic approach for the incorporation of unnatural amino acids into proteins | Q46473772 | ||
| Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. | Q48173267 | ||
| Antisense oligodeoxynucleotides to NMDA-R1 receptor channel protect cortical neurons from excitotoxicity and reduce focal ischaemic infarctions | Q48283998 | ||
| Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides | Q48345440 | ||
| Use of antisense vectors and oligodeoxynucleotides in neuro-oncology | Q48369457 | ||
| Keeping the biotechnology of antisense in context. | Q54157081 | ||
| LNA (Locked Nucleic Acids): Synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition | Q56289031 | ||
| A Novel Class of Oligonucleotide Analogues Containing 2‘-O,3‘-C-Linked [3.2.0]Bicycloarabinonucleoside Monomers: Synthesis, Thermal Affinity Studies, and Molecular Modeling | Q56956351 | ||
| Synthesis of 3‘-C- and 4‘-C-Branched Oligodeoxynucleotides and the Development of Locked Nucleic Acid (LNA) | Q59007889 | ||
| LNA (Locked Nucleic Acid): An RNA Mimic Forming Exceedingly Stable LNA:LNA Duplexes | Q59007996 | ||
| Purification and characterization of tyrosine hydroxylase from a clonal pheochromocytoma cell line | Q72425831 | ||
| Differential effects of intrastriatally infused fully and endcap phosphorothioate antisense oligonucleotides on morphology, histochemistry and prodynorphin expression in rat brain | Q73387828 | ||
| Antisense therapeutics | Q77297328 | ||
| Vitravene--another piece in the mosaic | Q77319598 | ||
| Mixed-backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects | Q77749810 | ||
| Antisense oligonucleotides - the way forward | Q84337936 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5633-5638 | |
| P577 | publication date | 2000-05-01 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | Potent and nontoxic antisense oligonucleotides containing locked nucleic acids | |
| P478 | volume | 97 |
| Q38300800 | 2'-O,4'-C-Methylene bridged nucleic acid (2',4'-BNA): synthesis and triplex-forming properties |
| Q38294110 | 2'-O,4'-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug |
| Q38305021 | 2'-fluoro-4'-thioarabino-modified oligonucleotides: conformational switches linked to siRNA activity. |
| Q38719143 | 6BIO Enhances Oligonucleotide Activity in Cells: A Potential Combinatorial Anti-androgen Receptor Therapy in Prostate Cancer Cells |
| Q64927668 | A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey. |
| Q59351655 | A highly sensitive 1-tube nested real-time RT-PCR assay using LNA-modified primers for detection of respiratory syncytial virus |
| Q47250939 | A mixed modality approach towards Xi reactivation for Rett syndrome and other X-linked disorders. |
| Q40090404 | A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides |
| Q92501821 | A novel lncRNA n384546 promotes thyroid papillary cancer progression and metastasis by acting as a competing endogenous RNA of miR-145-5p to regulate AKT3 |
| Q64265722 | A self-assembled, modular nucleic acid-based nanoscaffold for multivalent theranostic medicine |
| Q34464418 | A sensitive assay system to test antisense oligonucleotides for splice suppression therapy in the mouse liver. |
| Q55311034 | A stress-induced response complex (SIRC) shuttles miRNAs, siRNAs, and oligonucleotides to the nucleus. |
| Q26770355 | Advanced In vivo Use of CRISPR/Cas9 and Anti-sense DNA Inhibition for Gene Manipulation in the Brain |
| Q34267400 | Advances in Duchenne muscular dystrophy gene therapy |
| Q38199518 | Advances in targeted delivery of small interfering RNA using simple bioconjugates |
| Q37395054 | Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs |
| Q38292107 | Alpha-L-RNA (alpha-L-ribo configured RNA): synthesis and RNA-selective hybridization of alpha-L-RNA/alpha-L-LNA chimera. |
| Q38291843 | Alpha-LNA (locked nucleic acid with alpha-D-configuration): synthesis and selective parallel recognition of RNA. |
| Q39256509 | Amido-bridged nucleic acids (AmNAs): synthesis, duplex stability, nuclease resistance, and in vitro antisense potency |
| Q52664595 | Ammonium and arsenic trioxide are potent facilitators of oligonucleotide function when delivered by gymnosis. |
| Q34467738 | Amplification and re-generation of LNA-modified libraries |
| Q74179761 | Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide |
| Q37222630 | Anti-insulin-like growth factor-IIP3 DNAzymes inhibit cell proliferation and induce caspase-dependent apoptosis in human hepatocarcinoma cell lines |
| Q96302336 | Antisense Antibacterial Compounds |
| Q64102569 | Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease |
| Q47156365 | Antisense Oligonucleotides Targeting Y-Box Binding Protein-1 Inhibit Tumor Angiogenesis by Downregulating Bcl-xL-VEGFR2/-Tie Axes |
| Q34553851 | Antisense as a neuroscience tool and therapeutic agent |
| Q35105919 | Antisense growth inhibition of methicillin-resistant Staphylococcus aureus by locked nucleic acid conjugated with cell-penetrating peptide as a novel FtsZ inhibitor |
| Q52572766 | Antisense inhibition of RNase P: mechanistic aspects and application to live bacteria. |
| Q34396781 | Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design |
| Q79180129 | Antisense knockdown of PKC-alpha using LNA-oligos |
| Q33418637 | Antisense oligonucleotide therapies: the promise and the challenges from a toxicologic pathologist's perspective |
| Q35179429 | Antisense oligonucleotides for cancer therapy-an overview |
| Q64096491 | Antisense oligonucleotides: A primer |
| Q31089384 | Antisense properties of tricyclo-DNA |
| Q34992794 | Antisense therapy for cancer--the time of truth |
| Q34608717 | Antisense therapy in neurology |
| Q24682555 | Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications |
| Q51449777 | Application of locked nucleic acid-based probes in fluorescence in situ hybridization. |
| Q37619467 | Application of locked nucleic acids to improve aptamer in vivo stability and targeting function |
| Q88786417 | Assessment of configurations and chemistries of bridged nucleic acids-containing oligomers as external guide sequences: a methodology for inhibition of expression of antibiotic resistance genes |
| Q55642764 | Biochemical Properties of a Decoy Oligodeoxynucleotide Inhibitor of STAT3 Transcription Factor. |
| Q36918516 | Brothers in arms: DNA enzymes, short interfering RNA, and the emerging wave of small-molecule nucleic acid-based gene-silencing strategies. |
| Q33725585 | C5-alkynyl-functionalized α-L-LNA: synthesis, thermal denaturation experiments and enzymatic stability |
| Q38112723 | Canonical and non-canonical barriers facing antimiR cancer therapeutics |
| Q34120915 | Cellular MicroRNAs 200b and 429 Regulate the Epstein-Barr Virus Switch between Latency and Lytic Replication |
| Q38291584 | Cellular delivery of locked nucleic acids (LNAs). |
| Q36101387 | Chemical modification of gene silencing oligonucleotides for drug discovery and development |
| Q39314188 | Chemically modified oligonucleotide-increased stability negatively correlates with its efficacy despite efficient electrotransfer. |
| Q43168929 | Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol |
| Q40379692 | Cholesterol conjugated oligonucleotide and LNA: a comparison of cellular and nuclear uptake by Hep2 cells enhanced by streptolysin-O. |
| Q37189876 | Combined fluorescent in situ hybridization for detection of microRNAs and immunofluorescent labeling for cell-type markers |
| Q39777950 | Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA. |
| Q34989670 | Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model |
| Q34522704 | DNA analogues: from supramolecular principles to biological properties |
| Q37083226 | DNA mimics for the rapid identification of microorganisms by fluorescence in situ hybridization (FISH). |
| Q37153589 | DNAzymes and cardiovascular disease. |
| Q34233456 | Deficiency of GDNF Receptor GFRα1 in Alzheimer's Neurons Results in Neuronal Death |
| Q38290074 | Definition and identification of small RNA sponges: Focus on miRNA sequestration |
| Q37277384 | Delivery of RNAi-Based Oligonucleotides by Electropermeabilization |
| Q38288803 | Design and characterization of decoy oligonucleotides containing locked nucleic acids |
| Q24545871 | Design of LNA probes that improve mismatch discrimination |
| Q39600730 | Design of antisense oligonucleotides stabilized by locked nucleic acids |
| Q33833155 | Direct isolation of poly(A)+ RNA from 4 M guanidine thiocyanate-lysed cell extracts using locked nucleic acid-oligo(T) capture. |
| Q35721274 | Dissecting the target specificity of RNase H recruiting oligonucleotides using massively parallel reporter analysis of short RNA motifs. |
| Q33345599 | Dual effects of miR156-targeted SPL genes and CYP78A5/KLUH on plastochron length and organ size in Arabidopsis thaliana |
| Q38310166 | Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site |
| Q38342079 | Effect of LNA modifications on small molecule binding to nucleic acids |
| Q34080079 | Effect of chemical modifications on modulation of gene expression by duplex antigene RNAs that are complementary to non-coding transcripts at gene promoters |
| Q79948026 | Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice |
| Q33282788 | Efficient inhibition of HIV-1 expression by LNA modified antisense oligonucleotides and DNAzymes targeted to functionally selected binding sites |
| Q41192925 | Electronic Structures of LNA Phosphorothioate Oligonucleotides |
| Q26775176 | Emerging Roles for MicroRNAs in Perioperative Medicine |
| Q37588723 | Emerging oligonucleotide therapies for asthma and chronic obstructive pulmonary disease |
| Q34109542 | Emerging roles of microRNAs in the control of embryonic stem cells and the generation of induced pluripotent stem cells |
| Q73549542 | Enhanced allele-specific PCR discrimination in SNP genotyping using 3' locked nucleic acid (LNA) primers |
| Q35479646 | ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis |
| Q88881570 | Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts |
| Q38764098 | Exploiting microRNAs As Cancer Therapeutics |
| Q38287887 | Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. |
| Q36890491 | First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. |
| Q38669913 | Fluorinated Nucleotide Modifications Modulate Allele Selectivity of SNP-Targeting Antisense Oligonucleotides |
| Q35096493 | Functional genetics for all: engineered nucleases, CRISPR and the gene editing revolution |
| Q36617402 | Functional genomics of sex hormone-dependent neuroendocrine systems: specific and generalized actions in the CNS. |
| Q35936438 | Functional genomics to new drug targets |
| Q39202309 | Functionalization of the 3'-ends of DNA and RNA strands with N-ethyl-N-coupled nucleosides: a promising approach to avoid 3'-exonuclease-catalyzed hydrolysis of therapeutic oligonucleotides. |
| Q73410850 | Genomics for business |
| Q55652601 | High-Technology Therapy Using Biomolecules or Synthetic Compounds for HIV Inhibition |
| Q28756986 | Hitting bacteria at the heart of the central dogma: sequence-specific inhibition |
| Q35784534 | Hormonal symphony: steroid orchestration of gene modules for sociosexual behaviors |
| Q55398328 | Hydrogel-Assisted Antisense LNA Gapmer Delivery for In Situ Gene Silencing in Spinal Cord Injury. |
| Q57817509 | Identification of the Ribonuclease P Catalytic Subunit: Cleavage of a Target mRNA in the Presence of an External Guide Sequence |
| Q63761327 | Improved DNA Clamps by Stacking to Adjacent Nucleobases |
| Q59356127 | In Situ Detection of Adenovirus DNA and mRNA in Individual Cells |
| Q55394821 | In vitro inhibition of porcine reproductive and respiratory syndrome virus replication by short antisense oligonucleotides with locked nucleic acid modification. |
| Q39731474 | In vivo tumor growth inhibition and biodistribution studies of locked nucleic acid (LNA) antisense oligonucleotides |
| Q33953132 | Influenza A virus-generated small RNAs regulate the switch from transcription to replication |
| Q35960810 | Inhibition of AAC(6')-Ib-mediated resistance to amikacin in Acinetobacter baumannii by an antisense peptide-conjugated 2',4'-bridged nucleic acid-NC-DNA hybrid oligomer |
| Q37304179 | Inhibition of aac(6')-Ib-mediated amikacin resistance by nuclease-resistant external guide sequences in bacteria |
| Q34088908 | Inhibition of natural antisense transcripts in vivo results in gene-specific transcriptional upregulation. |
| Q45240198 | Inhibition of steroid receptor coactivator-1 blocks estrogen and androgen action on male sex behavior and associated brain plasticity. |
| Q34628844 | Internalization of Locked Nucleic Acids/DNA Hybrid Oligomers into Escherichia coli. |
| Q51469445 | Knockdown of Nuclear-Located Enhancer RNAs and Long ncRNAs Using Locked Nucleic Acid GapmeRs. |
| Q37490134 | LNA-based in situ hybridization detection of mRNAs in embryos |
| Q36142470 | LNA-based oligonucleotide electrotransfer for miRNA inhibition |
| Q39698230 | LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. |
| Q40969353 | LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. |
| Q33807788 | LNA/DNA mixmer-based antisense oligonucleotides correct alternative splicing of the SMN2 gene and restore SMN protein expression in type 1 SMA fibroblasts |
| Q34175818 | LNA: a versatile tool for therapeutics and genomics |
| Q34630862 | Labeling DNA for single-molecule experiments: methods of labeling internal specific sequences on double-stranded DNA |
| Q38349969 | Lack of efficacy of 'naked' small interfering RNA applied directly to rat brain. |
| Q41520047 | Locked Nucleic Acid Gapmers and Conjugates Potently Silence ADAM33, an Asthma-Associated Metalloprotease with Nuclear-Localized mRNA |
| Q59004652 | Locked Nucleic Acid Oligonucleotides toward Clinical Applications |
| Q37883000 | Locked and unlocked nucleosides in functional nucleic acids. |
| Q24794430 | Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality |
| Q59006209 | Locked nucleic acid (LNA): High affinity targeting of RNA for diagnostics and therapeutics |
| Q31967436 | Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. |
| Q40482458 | Locked nucleic acid containing antisense oligonucleotides enhance inhibition of HIV-1 genome dimerization and inhibit virus replication. |
| Q33832774 | Locked nucleic acid modified DNA enzymes targeting early growth response-1 inhibit human vascular smooth muscle cell growth |
| Q36440340 | Locked nucleic acid: high-affinity targeting of complementary RNA for RNomics. |
| Q38315404 | Locked nucleic acid: tighter is different. |
| Q42168773 | Locked nucleic acids: synthesis and characterization of LNA-T diol |
| Q37873745 | Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals |
| Q64931707 | Long non-coding RNAs in the failing heart and vasculature. |
| Q57295921 | Long noncoding RNA GM12371 acts as a transcriptional regulator of synapse function |
| Q36353705 | Long noncoding RNAs in cancer: from function to translation |
| Q38828951 | Managing the sequence-specificity of antisense oligonucleotides in drug discovery |
| Q33509127 | Metabotropic glutamate receptors: novel targets for pain relief |
| Q52005655 | MicroRNA expression during chick embryo development. |
| Q24644849 | MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction |
| Q88510369 | MicroRNA-based therapeutics in central nervous system injuries |
| Q37726449 | MicroRNA-mediated gene silencing |
| Q47654194 | MicroRNAs in Renal Diseases: A Potential Novel Therapeutic Target |
| Q38219675 | MicroRNAs in brain metastases: potential role as diagnostics and therapeutics. |
| Q38001790 | MicroRNAs in rheumatoid arthritis: potential role in diagnosis and therapy |
| Q27004814 | MicroRNAs in the pathophysiology and treatment of status epilepticus |
| Q35721717 | Microparticle-based delivery of oxytocin receptor antisense DNA in the medial amygdala blocks social recognition in female mice |
| Q38968703 | Modular Assembly of Cell-targeting Devices Based on an Uncommon G-quadruplex Aptamer |
| Q52642353 | Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. |
| Q38809725 | Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours |
| Q34153227 | Multielectrode recordings: the next steps. |
| Q46269669 | Multiple P2Y subtypes in spinal microglia are involved in neuropathic pain after peripheral nerve injury |
| Q44737925 | NMR and UV studies of 3'-S-phosphorothiolate modified DNA in a DNA : RNA hybrid dodecamer duplex; implications for antisense drug design |
| Q92942749 | Nano-sized carriers in gene therapy for peritoneal fibrosis in vivo |
| Q37444136 | Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA. |
| Q52589516 | Nanotechnology based approaches for detection and delivery of microRNA in healthcare and crop protection. |
| Q42153007 | New approaches for cancer treatment: antitumor drugs based on gene-targeted nucleic acids. |
| Q73339737 | New candidates for true antisense |
| Q39403581 | New pharmacological strategies for pain relief |
| Q54231141 | Non-Viral Based miR Delivery and Recent Developments. |
| Q37068616 | Nuclear antisense effects in cyclophilin A pre-mRNA splicing by oligonucleotides: a comparison of tricyclo-DNA with LNA |
| Q36049800 | Nuclease Activity of Saccharomyces cerevisiae Mre11 Functions in Targeted Nucleotide Alteration |
| Q79179835 | Nuclease Stability of LNA Oligonucleotides and LNA-DNA Chimeras |
| Q37338992 | Nucleic acids-based therapeutics in the battle against pathogenic viruses |
| Q38296788 | Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction |
| Q45002635 | Oligonucleotide technologies: synthesis, production, regulations and applications. 29-30th November 2000, Hamburg, Germany |
| Q38618638 | Oligonucleotide therapeutics: chemistry, delivery and clinical progress |
| Q48288187 | Oligonucleotide therapies for disorders of the nervous system |
| Q31013431 | Oligonucleotides and derivatives as gene-specific control agents |
| Q37937557 | Oligonucleotides: a multi-targeted approach for the treatment of respiratory diseases |
| Q33193599 | Oligonucleotide‐Based Knockdown Technologies: Antisense Versus RNA Interference |
| Q58183450 | On the in vitro and in vivo Properties of Four Locked Nucleic Acid Nucleotides Incorporated into an Anti-H-Ras Antisense Oligonucleotide |
| Q37567520 | Optimization of an AMBER force field for the artificial nucleic acid, LNA, and benchmarking with NMR of L(CAAU). |
| Q92440973 | Optimizing locked nucleic acid/2'-O-methyl-RNA fluorescence in situ hybridization (LNA/2'OMe-FISH) procedure for bacterial detection |
| Q37634460 | Pervasive transcription of a herpesvirus genome generates functionally important RNAs |
| Q40904618 | Position-dependent effects of locked nucleic acid (LNA) on DNA sequencing and PCR primers |
| Q37478933 | Progress in microRNA delivery |
| Q24604272 | Proinflammatory role for let-7 microRNAS in experimental asthma |
| Q38405255 | Quantum mechanical studies of DNA and LNA. |
| Q54295403 | Quick regulation of mRNA functions by a few seconds of photoirradiation. |
| Q35650955 | RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications |
| Q57174720 | RNA Therapeutics in Cardiovascular Precision Medicine |
| Q38349558 | RNA cleaving '10-23' DNAzymes with enhanced stability and activity |
| Q42048496 | RNAi therapy to the wall of arteries and veins: anatomical, physiologic, and pharmacological considerations |
| Q34659612 | RNAi-based therapeutics-current status, challenges and prospects |
| Q34257340 | RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1 |
| Q45851717 | Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro. |
| Q34393190 | Reduction of lipocalin-type prostaglandin D synthase in the preoptic area of female mice mimics estradiol effects on arousal and sex behavior |
| Q24603928 | Regulation of opioid tolerance by let-7 family microRNA targeting the mu opioid receptor |
| Q33850064 | Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators |
| Q36575303 | Retrieval of entire genes from environmental DNA by inverse PCR with pre-amplification of target genes using primers containing locked nucleic acids. |
| Q38335830 | Selection, optimization, and pharmacokinetic properties of a novel, potent antiviral locked nucleic acid-based antisense oligomer targeting hepatitis C virus internal ribosome entry site |
| Q56764556 | Selective recognition of CG interruption by 2′,4′-BNA having 1-isoquinolone as a nucleobase in a pyrimidine motif triplex formation |
| Q40938404 | Sensitive and specific detection of microRNAs by northern blot analysis using LNA-modified oligonucleotide probes |
| Q38296931 | Sensitive detection of nucleic acids by PNA hybridization directed co-localization of fluorescent beads |
| Q38308838 | Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides. |
| Q35237068 | Short antisense-locked nucleic acids (all-LNAs) correct alternative splicing abnormalities in myotonic dystrophy |
| Q29039090 | Silencing disease genes in the laboratory and the clinic |
| Q34425882 | Small players with big roles: microRNAs as targets to inhibit breast cancer progression |
| Q38288209 | Specific RNP capture with antisense LNA/DNA mixmers. |
| Q34117470 | Splice-correcting oligonucleotides restore BTK function in X-linked agammaglobulinemia model |
| Q35514689 | Stabilization and photochemical regulation of antisense agents through PEGylation. |
| Q24816245 | Stable transmission of targeted gene modification using single-stranded oligonucleotides with flanking LNAs |
| Q43591278 | Stereocontrolled synthesis of LNA dinucleoside phosphorothioate by the oxathiaphospholane approach |
| Q28359583 | Stopped-flow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions |
| Q38344609 | Strong positional preference in the interaction of LNA oligonucleotides with DNA polymerase and proofreading exonuclease activities: implications for genotyping assays |
| Q38594019 | Sugar-modified G-quadruplexes: effects of LNA-, 2'F-RNA- and 2'F-ANA-guanosine chemistries on G-quadruplex structure and stability |
| Q40037938 | Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy |
| Q33725529 | Synthesis and biophysical properties of C5-functionalized LNA (locked nucleic acid). |
| Q39752190 | Synthesis and physical and physiological properties of 4'-thioRNA: application to post-modification of RNA aptamer toward NF-kappaB |
| Q44416604 | Synthesis and properties of 2′-O,4′-C-Ethylene-Bridged nucleic acids (ENA) as effective antisense oligonucleotides |
| Q28706666 | Synthetic genomics and synthetic biology applications between hopes and concerns |
| Q35074291 | Target discovery and validation in the post-genomic era. |
| Q45007187 | Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides |
| Q78431346 | Targeted nucleotide exchange in Saccharomyces cerevisiae directed by short oligonucleotides containing locked nucleic acids |
| Q38110692 | Targeting long non-coding RNA to therapeutically upregulate gene expression |
| Q52549011 | Telomerase - strategies to exploit an important chemotherapeutic target. |
| Q92494785 | The Functions of Long Non-Coding RNA during Embryonic Cardiovascular Development and Its Potential for Diagnosis and Treatment of Congenital Heart Disease |
| Q52738891 | The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders. |
| Q27662137 | The crystal structure of an 'All Locked' nucleic acid duplex |
| Q36435632 | The future of antisense oligonucleotides in the treatment of respiratory diseases |
| Q28298317 | The microRNA miR-181 targets the homeobox protein Hox-A11 during mammalian myoblast differentiation |
| Q35205482 | The pain of antisense: in vivo application of antisense oligonucleotides for functional genomics in pain and analgesia. |
| Q35143897 | The potential of antisense as a CNS therapeutic |
| Q38815760 | The role of miRNAs in cardiovascular disease risk factors |
| Q26775558 | The structural diversity of artificial genetic polymers |
| Q57110142 | Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis |
| Q35615550 | Towards Fluorescence In Vivo Hybridization (FIVH) Detection of H. pylori in Gastric Mucosa Using Advanced LNA Probes |
| Q37520915 | Transcription factor decoy oligonucleotides modified with locked nucleic acids: an in vitro study to reconcile biostability with binding affinity. |
| Q38300047 | Transcription factor decoy: a pre-transcriptional approach for gene downregulation purpose in cancer |
| Q38353733 | Triplex formation with 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) having C3'-endo conformation at physiological pH. |
| Q24810418 | Triplex-induced recombination and repair in the pyrimidine motif |
| Q35813873 | Unravelling the general properties of siRNAs: strength in numbers and lessons from the past |
| Q30421636 | Updated values for molecular diagnosis for highly pathogenic avian influenza virus |
| Q38349562 | Use of locked nucleic acid oligonucleotides to add functionality to plasmid DNA |
| Q27860886 | Widespread changes in protein synthesis induced by microRNAs |
| Q37985651 | Xenopus: an ideal system for chemical genetics. |
| Q38092617 | miRNA-Based Therapeutic Strategies |
| Q38521725 | microRNA therapies in cancer |
| Q38472671 | microRNAs in CNS disorders |
Search more.